Τίτλος:
Cancer therapy and the heart; the necessity to calibrate risk
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Συγγραφείς:
Okwuosa, T.M.
Keramida, K.
Filippatos, G.
Yancy, C.W.
Περιοδικό:
European Journal of Heart Failure
Εκδότης:
John Wiley and Sons Ltd
Λέξεις-κλειδιά:
anthracycline; antiandrogen; antineoplastic agent; immune checkpoint inhibitor; immunomodulating agent; mitogen activated protein kinase kinase inhibitor; phosphotransferase inhibitor; proteasome inhibitor; protein inhibitor; Raf protein inhibitor; unclassified drug; vasculotropin inhibitor, algorithm; cancer chemotherapy; cancer patient; cardiologist; cardiotoxicity; cardiovascular disease; cardiovascular risk; childhood cancer; cytology; delayed diagnosis; disease risk assessment; drug exposure; echocardiography; Editorial; genomics; heart arrhythmia; heart failure; heart injury; high risk patient; human; hypertension; ischemia; malignant neoplasm; medical expert; metabolic syndrome X; myocarditis; oncologist; practice guideline; priority journal; proteomics; QT prolongation; risk assessment; risk benefit analysis; risk management; risk reduction; shared decision making; therapy delay; thromboembolism; cardiology; cardiovascular disease; heart failure; neoplasm; risk factor, Cardiology; Cardiovascular Diseases; Heart Disease Risk Factors; Heart Failure; Humans; Neoplasms; Risk Assessment; Risk Factors
